InsidersTradesSigma
Follow the Arvinas Inc share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €592.3m. The latest transaction was reported on 23 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Andrew Saik. All data is openly available.
Analysts rate Arvinas Inc Buy (bullish), based on 14 analysts. Average price target: US$13.93.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Arvinas Inc 是一家生物制药公司，专注于开发基于蛋白质降解的疗法。该公司在纳斯达克上市，股票代码为 ARVN。